Presentation during EHA21: On Saturday, June 11, 2016 from 12:30 - 12:45
Location: Hall A1
Background Btk is a kinase involved in B-cell receptor signaling and a critical therapeutic target in CLL. Acalabrutinib—an irreversible, selective Btk inhibitor has demonstrated clinical efficacy in relapsed CLL (Byrd NEJM 2015).
Aims Here, we present preliminary results from an ongoing Phase 1-2 study of acalabrutinib monotherapy in patients (pts) with previously untreated CLL.
Methods Pts with previously untreated CLL who met IWCLL 2008 criteria for treatment were eligible, irrespective of any cytopenias. Pts received oral acalabrutinib at 100 mg BID (n = 37) or 200 mg QD (n = 37). Pts had a median age of 64 (48-85) years, bulky lymph nodes ≥ 5 cm (47%) and unmutated IGHV gene (57%, 38/67). CLL responses were assessed per modified IWCLL criteria.
Results Results are presented through 07Dec2015 for the first 74 treated pts, including 72 evaluable for response. Median time on study (N = 74) was 11 (1-15) months. Acalabrutinib was well tolerated with 97% (72/74) of pts continuing on study drug. Most AEs were Grade (Gr) ≤ 2. The most common Gr 1-2 AEs ( ≥ 15% pts) were headache (42%), diarrhea (35%), arthralgia (22%), contusion (18%), nausea (18%) and increased weight (18%). Gr 3-4 AEs that occurred in ≥ 2 pts were syncope (n = 2, both Gr 3) and hypertension (n = 2, both Gr 3). One Gr 5 event (pneumonia) has occurred. One Gr 3 upper GI bleed due to a gastric ulcer and aspirin use has occurred. No atrial fibrillation was reported. Clinical activity was observed with both dose schedules; Btk occupancy was highest with BID dosing (98% vs 93% predose at Day 28). All pts had a rapid reduction in lymphadenopathy. Treatment-related lymphocytosis occurred in 53% (39/74) of pts and resolved in 97% (38/39) of these pts. In general, lymphocytosis peaked at a median of 1 week and resolved by a median of 7 (3-15) weeks. Best ORR was 96% (PR = 86%, PR+L = 10%, SD = 4%, PD = 0%). Median time to response was 2 (2-8) months. No CLL progression or Richter’s transformation have occurred.
Conclusion In pts with previously untreated CLL, a favorable safety profile and high response rates that appear durable were observed with acalabrutinib therapy. Based on these results, a Phase 3 trial has commenced (NCT02475681).
Session topic: Innovative therapies in CLL
Keyword(s): B cell chronic lymphocytic leukemia, Kinase inhibitor
Abstract: S431
Type: Oral Presentation
Presentation during EHA21: On Saturday, June 11, 2016 from 12:30 - 12:45
Location: Hall A1
Background Btk is a kinase involved in B-cell receptor signaling and a critical therapeutic target in CLL. Acalabrutinib—an irreversible, selective Btk inhibitor has demonstrated clinical efficacy in relapsed CLL (Byrd NEJM 2015).
Aims Here, we present preliminary results from an ongoing Phase 1-2 study of acalabrutinib monotherapy in patients (pts) with previously untreated CLL.
Methods Pts with previously untreated CLL who met IWCLL 2008 criteria for treatment were eligible, irrespective of any cytopenias. Pts received oral acalabrutinib at 100 mg BID (n = 37) or 200 mg QD (n = 37). Pts had a median age of 64 (48-85) years, bulky lymph nodes ≥ 5 cm (47%) and unmutated IGHV gene (57%, 38/67). CLL responses were assessed per modified IWCLL criteria.
Results Results are presented through 07Dec2015 for the first 74 treated pts, including 72 evaluable for response. Median time on study (N = 74) was 11 (1-15) months. Acalabrutinib was well tolerated with 97% (72/74) of pts continuing on study drug. Most AEs were Grade (Gr) ≤ 2. The most common Gr 1-2 AEs ( ≥ 15% pts) were headache (42%), diarrhea (35%), arthralgia (22%), contusion (18%), nausea (18%) and increased weight (18%). Gr 3-4 AEs that occurred in ≥ 2 pts were syncope (n = 2, both Gr 3) and hypertension (n = 2, both Gr 3). One Gr 5 event (pneumonia) has occurred. One Gr 3 upper GI bleed due to a gastric ulcer and aspirin use has occurred. No atrial fibrillation was reported. Clinical activity was observed with both dose schedules; Btk occupancy was highest with BID dosing (98% vs 93% predose at Day 28). All pts had a rapid reduction in lymphadenopathy. Treatment-related lymphocytosis occurred in 53% (39/74) of pts and resolved in 97% (38/39) of these pts. In general, lymphocytosis peaked at a median of 1 week and resolved by a median of 7 (3-15) weeks. Best ORR was 96% (PR = 86%, PR+L = 10%, SD = 4%, PD = 0%). Median time to response was 2 (2-8) months. No CLL progression or Richter’s transformation have occurred.
Conclusion In pts with previously untreated CLL, a favorable safety profile and high response rates that appear durable were observed with acalabrutinib therapy. Based on these results, a Phase 3 trial has commenced (NCT02475681).
Session topic: Innovative therapies in CLL
Keyword(s): B cell chronic lymphocytic leukemia, Kinase inhibitor
By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS). USER TERMS AND CONDITIONS | PRIVACY POLICY
Cookie Settings Accept Terms & all Cookies
Anonymous User Privacy Preferences
Strictly Necessary Cookies (Always Active)
MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.
Performance Cookies
Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.
Google Analytics and Google Tag Manager embedded tracking functionalities are used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG's features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.